News

News Archive

Le Volpi Rosse Menarini conquistano il secondo posto all'Eurocup 3

Le Volpi Rosse Menarini conquistano il secondo posto all'Eurocup 3

Content available only in italian language

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

Malvern, PA, Parsippany, NJ, and Florence, Italy - February 20, 2024 – Venatorx Pharmaceuticals,  Melinta Therapeutics LLC (“Melinta”), and Menarini Group today...
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

Malvern, PA, and Florence, Italy, January 9th, 2024  – Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for...
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

FLORENCE, Italy and NEW YORK, January 4, 2024: The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline...
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)

FLORENCE, Italy and NEW YORK, December 11, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and...
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, December 8, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and...
1345678910Last

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Go to Follow our blog

Follow our blog

Discover our stories from all over the world

Read More